MOMIPP

SKU: orb1304300

Description

MOMIPP is a small molecule inhibitor of PIKfyve that potently induces macropinocytosis. It demonstrates blood-brain barrier permeability and has shown moderate efficacy in slowing the progression of intracerebral glioblastoma tumors in xenograft models, supporting its use in oncology and cell biology research.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1363421-46-8
• MW: 292.33
• Purity: 99.92% (May vary between batches)
• Formula: C₁₈H₁₆N₂O₂
• SMILES: COc1ccc2[nH]c(C)c(\C=C\C(=O)c3ccncc3)c2c1
• Target: PI3K
• Solubility: DMSO:15.13 mg/mL (51.76 mM)

Bioactivity

• In Vivo:
  MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows result that MOMIPP is moderately effective in suppressing progression of intracerebral glioblastoma xenografts.
  Read more...
• In Vitro:
  MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations. MOMIPP(3 μM) induces cell vacuolization in U373 and Hs683 cell lines. The cytotoxic IPP compound, MOMIPP, causes early disruptions of glucose uptake and glycolytic metabolism. Coincident with these metabolic changes, MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL.
  Read more...
• Cell Research:
  When JNK activation (phosphorylation) was assessed by western blot analysis after 24 h, MOMIPP(10 μM)has been found that induced major increases in JNK1/2 phosphorylation.
  Read more...
• Animal Research:
  MOMIPP (Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks); 80 mg/kg; i.p.; once daily; for 15 consecutive days) suppressed progression of intracerebral glioblastoma xenografts.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

JNK1/2, inhibit, Inhibitor, Macropinocytosis, MOMIPP, Fab1, c-Jun, BBB, Bcl-2, Bcl-xL, PIKfyve

Compound Identifiers

PubChem CID

51039247